Lates News

According to the AI Fast News of Every Economic, China Post Securities released a research report on April 24th, giving a "buy" rating to Pharmaron (000739.SZ). The main reasons for the rating include: 1) The CDMO business is entering an accelerated period, with the core engine driving high-quality growth; 2) API product structure optimization, significant cost reduction and efficiency improvement; 3) Technological platform and advanced production capacity barriers are reinforced, accumulating strength for medium to long-term growth. (Daily Economic News)